Nothing Special   »   [go: up one dir, main page]

AR076694A1 - Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion - Google Patents

Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion

Info

Publication number
AR076694A1
AR076694A1 ARP100101771A ARP100101771A AR076694A1 AR 076694 A1 AR076694 A1 AR 076694A1 AR P100101771 A ARP100101771 A AR P100101771A AR P100101771 A ARP100101771 A AR P100101771A AR 076694 A1 AR076694 A1 AR 076694A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
hydroxyalkyl
haloalkyl
independently
Prior art date
Application number
ARP100101771A
Other languages
English (en)
Inventor
Tsze H Tsang
Charles M Blazey
Cristina A Zaharia
Owen Joseph Bowles
Amy L Tsuhako
Joerg Bussenius
Chris Allen Buhr
Jason R Harris
Angie Inyoung Kim
Anagha Joshi
Stephanie Ng
Csaba J Peto
Neel Kumar Anand
Kenneth D Rice
Steven Charles Defina
Larisa Dubenko
Sunghoon Ma
Jeffry Kimo Curtis
Eileen Jackson-Ugueto
Jean-Claire Limun Manalo
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AR076694A1 publication Critical patent/AR076694A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se preveen composiciones farmacéuticas que comprenden métodos para preparar y uso de los compuestos en el tratamiento del cáncer. Reivindicacion 1: Un compuesto de la formula 1: o uno de sus estereoisomeros individuales o una mezcla de estereoisomeros y además, opcionalmente como una de sus sales farmacéuticamente aceptables, en donde R1es fenilo opcionalmente sustituido con uno, dos o tres grupos R6 o R1 es heteroarilo opcionalmente sustituido con uno, dos o tres R7 R2 es heteroarilo sustituido con R3, R3a, R3b, R3c y R3d; R3, R3a, R3b, R3c y R3d son, de modo independiente, hidrogeno, ciano, alquilo, alquenilo, halo, haloalquilo, hidroxialquilo, alcoxialquilo, cianoalquilo, -SR12, -S(O) 2R20, -C(O)OR4, halocarbonilo, -NR11R11a, -OR11a fenilo opcionalmente sustituido, fenilalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilalquilo opcionalmente sustituido o alquilo sustituido con uno o dos R16 o dos de R3, R3a, R3b, R3c y R3d cuando se unen con el mismo carbono, forman un cicloalquilo opcionalmente sustituido o un heterocicloalquilo opcionalmente sustituido; y el otro de R3, R3a, R3b, R3c y R3d son, de modo independiente, hidrogeno, ciano, alquilo, alquenilo, halo, haloalquilo, hidroxialquilo, alcoxialquilo, cianoalquilo, -SR12, -S(O)2R20, -C(O)OR4, halocarbonilo, -NR11R11a, -OR11a, fenilo opcionalmente sustituido, fenilalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquilalquilo opcionalmente sustituido, heteroarilo opcionalmente, heteroarilalquilo opcionalmente sustituido o alquilo sustituido con uno o dos R16 R4 es alquilo, alquenilo, alquinilo, hidroxialquilo, alcoxialquilo, haloalquilo, bencilo o heterocicloalquilalquilo opcionalmente sustituido; R5a y R5c son, de modo independiente, hidrogeno o alquilo; R5h es hidrogeno o halo; R5b es hidrogeno, amino o halo; R5d, R5e, R5f y R5g son hidrogeno; cada R6, cuando R6 está presente, es, de modo independiente, nitro; ciano; halo; alquilo; alquenilo; alquinilo; haloalquilo; -OR8a; -NR8R8a; -C(O)NR8R8a; - S(O)2R8, -NR8C(O)OR9, -NR8C(O)R9, -NR8S(O)2R8a;. -NR8C(O)NR8aR9 carboxi, -C(O)OR9 halocarbonilo; alquilcarbonilo; alquilo sustituido con uno o dos -C(O)NR8R8a; heteroarilo opcionalmente sustituido con 1, 2 o 3 R14; o heterocicloalquilo opcionalmente sustituido; cada R7, cuando R7 está presente, es, de modo independiente, oxo; nitro; ciano; alquilo; alquenilo; alquinilo; halo; haloalquilo; hidroxialquilo; alcoxialquilo; -OR8a; -SR13 -S(O)R13a, -S(O)2R13a; -NR8R8a; -C(O)NR8R8a, -NR8C(O)OR9, -NR8C(O)R9; -NR8S(O)2R8a; -NR8C(O)NR8aR9, -C(O)OR9 halocarbonilo; alquilcarbonilo; -S(O)2NR8R9 alquilsulfonilalquilo; alquilo sustituido con uno o dos -NR8R8a; alquilo sustituido con uno o dos -NR8C(O)R8a; alquilo sustituido, con uno o dos -NR8C(O)OR9 alquilo sustituido con uno o dos -S(O)2R13a; cicloalquilo opcionalmente sustituido; cicloalquilalquilo opcionalmente sustituido; heterocicloalquilo opcionalmente sustituido; heterocicloalquilalquilo opcionalmente sustituido; fenilo opcionalmente sustituido; fenilalquilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; o heteroarilalquilo opcionalmente sustituido; cada R8, R11, R15, R17 y R18 es, de modo independiente, hidrogeno, alquilo, alquenilo, alquinilo, hidroxialquilo, alcoxialquilo o haloalquilo; cada R8a, R11a , R15a es, de modo independiente, hidrogeno, alquilo, alquenilo, alquinilo, haloalquilo, hidroxialquilo, cianoalquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, alcoxialquilo, carboxialquilo, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquilalquilo opcionalmente sustituido, fenilo opcionalmente sustituido, fenilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroarilalquilo opcionalmente sustituido; R9 es hidrogeno; alquilo; alquenilo; alquinilo; hidroxialquilo; alcoxialquilo; aminoalquilo; alquilaminoalquilo; dialquilaminoalquilo; haloalquilo; hidroxialquilo sustituido con uno, dos o tres grupos que son, de modo independiente, halo, amino, alquilamino o dialquilamino; alquilo sustituido con uno o dos aminocarbonilo; fenilo opcionalmente sustituido; fenilalquilo opcionalmente sustituido; cicloalquilo opcionalmente sustituido; cicloalquilalquilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; heteroarilalquilo opcionalmente sustituido; heterocicloalquilo opcionalmente sustituido; o heterocicloalquilalquilo opcionalmente sustituido; R12 es alquilo o fenilalquilo opcionalmente sustituido; R13 es alquilo, hidroxialquilo o haloalquilo; y R13a es hidroxi, alquilo, haloalquilo, hidroxialquilo o heterocicloalquilo opcionalmente sustituido con uno o dos grupos que son, de modo independiente, halo, amino, alquilamino, dialquilamino, hidroxi, alquilo o hidroxialquilo; cada R14, cuando R14 está presente, es, de modo independiente, amino, alquilamino, dialquilamino, acilamino, halo, hidroxi, alquilo, haloalquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, alcoxicarbonilo, aminocarbonilo, alquilaminocarbonilo, dialquilaminocarbonilo o fenilo opcionalmente sustituido; cada R16 es, de modo independiente, -NR11R12a, -NR15S(O)R15a, -OC(O)R17 u -OR18 y R20 es alquilo, haloalquilo, hidroxialquilo, amino, alquilamino, dialquilamino o heterocicloalquilo.
ARP100101771A 2009-05-22 2010-05-21 Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion AR076694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21698009P 2009-05-22 2009-05-22

Publications (1)

Publication Number Publication Date
AR076694A1 true AR076694A1 (es) 2011-06-29

Family

ID=42556812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101771A AR076694A1 (es) 2009-05-22 2010-05-21 Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion

Country Status (13)

Country Link
US (1) US8648066B2 (es)
EP (1) EP2432779A1 (es)
JP (1) JP2012527474A (es)
KR (1) KR20120034666A (es)
CN (1) CN102459249A (es)
AR (1) AR076694A1 (es)
AU (1) AU2010249790A1 (es)
BR (1) BRPI1010974A2 (es)
CA (1) CA2763099A1 (es)
IL (1) IL216472A0 (es)
MX (1) MX2011012345A (es)
TW (1) TW201111371A (es)
WO (1) WO2010135524A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
ES2425091T3 (es) 2009-05-26 2013-10-11 Exelixis, Inc. Benzoxazepinas como inhibidores de PI3K/mTOR y sus métodos de uso y fabricación
WO2010151737A2 (en) * 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
EP3170813B1 (en) 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazole derivatives as pi3 kinase inhibitors
DE102010049595A1 (de) * 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
US20140080810A1 (en) * 2010-11-15 2014-03-20 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
WO2012068106A2 (en) * 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
CA2818889A1 (en) * 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
MX2013005821A (es) * 2010-11-24 2013-08-27 Exelixis Inc Benzoxazepinas como inhibidores de fosfatidilinositol/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
KR20140000706A (ko) * 2010-11-24 2014-01-03 엑셀리시스, 인코포레이티드 PI3K/mTOR의 억제제로서의 벤즈옥사제핀 및 그의 이용 방법 및 제법
US20140018347A1 (en) * 2010-11-24 2014-01-16 Exelixis, Inc. BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE
EP3581574A1 (en) 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease
KR20140032383A (ko) * 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
CA2834548C (en) * 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP6062432B2 (ja) * 2011-07-27 2017-01-18 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． プロテインキナーゼ阻害薬用スピロ環状分子
WO2013067141A1 (en) 2011-11-01 2013-05-10 Exelixis, Inc. N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
JP5949070B2 (ja) * 2012-04-03 2016-07-06 Jsr株式会社 液晶配向剤、液晶配向膜及び液晶表示素子
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI633087B (zh) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
WO2014048865A1 (en) 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag New bicyclic derivatives
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JP6496730B2 (ja) 2013-11-26 2019-04-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規なオクタヒドロ−シクロブタ［１，２−ｃ；３，４−ｃ’］ジピロール−２−イル
JP2017502092A (ja) 2014-01-14 2017-01-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリール及びその使用
KR20160122736A (ko) 2014-01-14 2016-10-24 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 이의 용도
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
AU2015238541B2 (en) 2014-03-26 2019-09-19 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN104910158B (zh) * 2015-06-15 2017-04-12 河南师范大学 具有生物活性的5,6,7,8‑四氢吡啶并[3,4‑d]嘧啶化合物及其制备方法和应用
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
CA2983782A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MX2017015034A (es) 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
US11028099B2 (en) * 2016-12-15 2021-06-08 Glaxosmithkline Intellectual Property Development Limited NRF2 activators
BR112019019017A2 (pt) 2017-03-16 2020-04-14 Hoffmann La Roche compostos heterocíclicos de utilidade como inibidores duplos de atx/ca
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
LT3448859T (lt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Pirolpirolo kompozicijos, kaip piruvato kinazės (pkr) aktyvatoriai
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
KR20240140193A (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
KR20240140187A (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
BR112022013169A2 (pt) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
AU2021251341A1 (en) 2020-04-07 2022-11-03 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024145259A2 (en) * 2022-12-28 2024-07-04 Reservoir Neuroscience, Inc. Ep2 antagonist compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102103A1 (de) 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2241724A1 (en) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
TR199801254T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r� antagonistleri.
SE9701681D0 (sv) * 1997-05-05 1997-05-05 Astra Ab New compounds
CA2358855A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
CZ2002722A3 (cs) 1999-08-27 2002-10-16 The Procter & Gamble Company Bělící prostředek obsahující organickou katalytickou sloučeninu a způsob praní látek ho pouľívající
BR0013616B1 (pt) 1999-08-27 2011-12-27 composiÇço de alvejamento e composto catalisador orgÂnico de lavanderia.
CZ2002723A3 (cs) 1999-08-27 2002-10-16 The Procter & Gamble Company Prací přípravky s kontrolovaným uvolňováním jejich sloľek a způsob pouľití těchto pracích přípravků
CA2382119A1 (en) 1999-08-27 2001-03-08 The Procter & Gamble Company Fast-acting formulation components, compositions and laundry methods employing same
US6723752B2 (en) * 1999-09-23 2004-04-20 Pharmacia Corporation (R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1463719A2 (en) 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
CN101258136A (zh) * 2005-07-05 2008-09-03 阿斯利康(瑞典)有限公司 新化合物、其制备方法、中间体、药物组合物和其在治疗5－ht6介导的疾病例如阿尔茨海默病、认知障碍、精神分裂症相关的认知缺损、肥胖和帕金森病中的用途
US20080234300A1 (en) 2007-03-05 2008-09-25 Wyeth Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof
US7691851B2 (en) * 2007-03-07 2010-04-06 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
WO2009026444A1 (en) 2007-08-22 2009-02-26 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
US20100197657A1 (en) * 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
JP5650540B2 (ja) 2007-12-12 2015-01-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
CN101497612A (zh) 2009-03-03 2009-08-05 北京华禧联合科技发展有限公司 一类新喹诺酮类化合物及其制备与用途
ES2425091T3 (es) * 2009-05-26 2013-10-11 Exelixis, Inc. Benzoxazepinas como inhibidores de PI3K/mTOR y sus métodos de uso y fabricación

Also Published As

Publication number Publication date
JP2012527474A (ja) 2012-11-08
US20100298290A1 (en) 2010-11-25
BRPI1010974A2 (pt) 2019-09-24
KR20120034666A (ko) 2012-04-12
EP2432779A1 (en) 2012-03-28
TW201111371A (en) 2011-04-01
CA2763099A1 (en) 2010-11-25
AU2010249790A1 (en) 2011-12-08
CN102459249A (zh) 2012-05-16
WO2010135524A8 (en) 2012-01-12
WO2010135524A1 (en) 2010-11-25
US8648066B2 (en) 2014-02-11
MX2011012345A (es) 2012-01-31
IL216472A0 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
AR076694A1 (es) Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion
AR076271A1 (es) Inhibidores de mtor, composiciones farmaceuticas, metodo de fabricacion y su uso en el tratamiento de cancer
AR076922A1 (es) Benzodiazepinas como inhibidores de pi3k/mtor, una composicion farmaceutica que las comprende, metodos para su fabricacion y su uso en el tratamiento del cancer.
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR083199A1 (es) Compuestos de n-heteroarilo con unidad de puente ciclico
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
NI201400023A (es) Derivados de pirrolopirimidina y purina
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CR20140091A (es) Nuevos derivados dihidroquinolina-2-ona
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
CO6140024A2 (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR081075A1 (es) Derivados de imidazo[1,2-c]pirimidina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias.
AR086972A1 (es) Procesos para preparar compuestos heterociclicos, que incluyen trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma
RU2015121431A (ru) Замещенные производные индол-5-ола и их терапевтическое применение
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
AR060590A1 (es) Compuestos imidazo
AR089776A1 (es) 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR069364A1 (es) Derivados heterociclicos que modulan la miosina del musculo liso y/o la miosina no muscular y composiciones farmaceuticas que los contienen
UY35845A (es) ?derivados de purina?.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal